摘要
乳腺癌是世界范围内女性发病率最高的恶性肿瘤。三阳性乳腺癌(TPBC)作为一种特殊类型的乳腺癌,在生物学特性、临床特征、治疗模式等方面与单纯HER2阳性或HR阳性乳腺癌存在差异。目前,TPBC的治疗以抗HER2治疗为主线,但其治疗策略仍存在一定争议。本文主要就TPBC的药物治疗进展进行综述。
Breast cancer is the most common malignant tumor with the highest incidence rate among women worldwide.As a special type of breast cancer,triple positive breast cancer(TPBC)is different from HER2-positive or HR-positive breast cancer in terms of biological characteristics,clinical features and treatment modes.At present,anti-HER2 therapy is still the main treatment for TPBC,but its treatment strategy remians controversial.This paper mainly reviews the progress of drug treatment of TPBC.
作者
陈飞
葛睿
瞿菲
张凌捷
CHEN Fei;GE Rui;QU Fei;ZHANG Lingjie(Department of General Surgery,the People’s Hospital of Putuo District,Shanghai,200060,China;Department of General Surgery,Huadong Hospital Affiliated to Hehai University,Shanghai,200040,Shanghai,200060,China;the First Affili-ated Hospital of Nanjing Medical University,Nanjing,210029,Jiangsu,China)
出处
《肿瘤药学》
CAS
2022年第6期690-695,共6页
Anti-Tumor Pharmacy
基金
上海市医苑新星青年医学人才培养资助计划[沪卫人事(2012)114号]。
关键词
三阳性乳腺癌
药物治疗
靶向治疗
研究进展
Triple positive breast cancer
Drug therapy
Targeted therapy
Research progress
